Stockreport

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) [Yahoo! Finance]

Kazia Therapeutics Limited - American Depositary Shares  (KZIA) 
US:NASDAQ Investor Relations: kaziatherapeutics.com
PDF SYDNEY Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat can [Read more]